Kiyo-Aki Ishii
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kiyo-Aki Ishii has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Toshinari Takamura
Department of Endocrinology and Metabolism Kanazawa University Graduate School of Medical Sciences Kanazawa Japan
6 shared publications Kyoko Kamoshita
Department of Endocrinology and Metabolism, Kanazawa University Graduate School of Medical Sciences , Ishikawa 920-8640
4 shared publications- Cynthia Monserrat Galicia-Medina
Department of Endocrinology and Metabolism, Kanazawa University Graduate School of Medical Sciences , Kanazawa 920-8640
3 shared publications Halimulati Abuduwaili
Department of Endocrinology and Metabolism, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan
3 shared publicationsHein Ko Oo
Department of Endocrinology and Metabolism, Kanazawa University Graduate School of Medical Sciences , Ishikawa 920-8640
3 shared publicationsHiroaki Takayama
Life Sciences Division, Engineering and Technology Department, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan
3 shared publications
Latest Publications
- 25 September 2026
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
Hepatic selenoprotein P impairs bone formation via osteoblastic IGF-1 resistance
Bone fragility is increasingly recognized as a complication of metabolic dysfunction, but endocrine mechanisms linking hepatic stress to impaired bone formation remain incompletely defined. We tested whether selenoprotein P, a hepatokine elevated in metabolic disease, suppresses osteoblast function and skeletal integrity. In mice fed a high-fat, high-sucrose diet, whole-body Selenop deficiency preserved trabecular bone mass, bone formation, bone stiffness, and cortical bone defect repair. Hepatocyte-specific Selenop deficiency also preserved trabecular bone mass. Histomorphometry showed that selenoprotein P primarily suppressed osteoblast activation without materially altering osteoclast indices. In calvaria-derived osteoblast cultures, purified human plasma-derived selenoprotein P inhibited IGF-1-induced phosphorylation of IGF-1 receptor, IRS-1, PI3K, PDK1, and Akt, reduced alkaline phosphatase activity, matrix mineralization, and osteogenic gene expression, and blunted receptor-proximal ROS generation. LRP1 was the predominant candidate receptor during osteogenic differentiation. Osteoblast cultures derived from Osx-Cre/+ Lrp1fl/fl mice showed reduced cell-associated human selenoprotein P, and the inhibitory effects of selenoprotein P on IGF-1 signaling and osteoblast maturation were absent in these cultures. In vivo, pharmacologic blockade of IGF-1 receptor signaling eliminated the skeletal protection conferred by Selenop deficiency, supporting a requirement for intact IGF-1 receptor signaling in this pathway. In a cross-sectional analysis of a general population cohort, serum selenoprotein P was not significantly associated with osteo-sono assessment index across the full cohort, whereas exploratory analyses in the highest quintile suggested an inverse association between high circulating selenoprotein P and bone mass. Together, these findings identify hepatic selenoprotein P as a negative regulator of bone formation and define a hepato-osteogenic reductive stress axis that links metabolic stress to impaired skeletal integrity.
- 25 September 2026
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
Hepatic selenoprotein P impairs bone formation via osteoblastic IGF-1 resistance
Bone fragility is increasingly recognized as a complication of metabolic dysfunction, but endocrine mechanisms linking hepatic stress to impaired bone formation remain incompletely defined. We tested whether selenoprotein P, a hepatokine elevated in metabolic disease, suppresses osteoblast function and skeletal integrity. In mice fed a high-fat, high-sucrose diet, whole-body Selenop deficiency preserved trabecular bone mass, bone formation, bone stiffness, and cortical bone defect repair. Hepatocyte-specific Selenop deficiency also preserved trabecular bone mass. Histomorphometry showed that selenoprotein P primarily suppressed osteoblast activation without materially altering osteoclast indices. In calvaria-derived osteoblast cultures, purified human plasma-derived selenoprotein P inhibited IGF-1-induced phosphorylation of IGF-1 receptor, IRS-1, PI3K, PDK1, and Akt, reduced alkaline phosphatase activity, matrix mineralization, and osteogenic gene expression, and blunted receptor-proximal ROS generation. LRP1 was the predominant candidate receptor during osteogenic differentiation. Osteoblast cultures derived from Osx-Cre/+ Lrp1fl/fl mice showed reduced cell-associated human selenoprotein P, and the inhibitory effects of selenoprotein P on IGF-1 signaling and osteoblast maturation were absent in these cultures. In vivo, pharmacologic blockade of IGF-1 receptor signaling eliminated the skeletal protection conferred by Selenop deficiency, supporting a requirement for intact IGF-1 receptor signaling in this pathway. In a cross-sectional analysis of a general population cohort, serum selenoprotein P was not significantly associated with osteo-sono assessment index across the full cohort, whereas exploratory analyses in the highest quintile suggested an inverse association between high circulating selenoprotein P and bone mass. Together, these findings identify hepatic selenoprotein P as a negative regulator of bone formation and define a hepato-osteogenic reductive stress axis that links metabolic stress to impaired skeletal integrity.
- Open Access
LRP1 is an entry receptor for the botulinum toxin complex in the gut
Botulinum neurotoxin (BoNT) is an etiologic agent of food poisoning caused by Clostridium botulinum . The large progenitor toxin complex (L-PTC) crosses the intestinal epithelial barrier to deliver BoNT to target neurons; however, it is not clearly understood how BoNT enters the host. Here, we identified low-density lipoprotein receptor−related protein 1 (LRP1) as a major enterocyte transcytosis receptor for the hyper-oral-toxic L-PTC serotype B-Okra (L-PTC/B Okra ). We found that hemagglutinin (HA), a neurotoxin-associated protein within the L-PTC/B Okra complex, binds to LRP1 via N -glycans. HA/B Okra co-localized with LRP1 within the internalized vesicles in cultured cells and enterocytes. LRP1 deletion inhibited the apical-to-basal transcytosis of L-PTC/B Okra in an intestinal epithelial cell line, and this effect was rescued by LRP1 re-expression. Finally, intestinal epithelial cell−specific LRP1-deficient mice displayed reduced susceptibility to toxicity caused by oral administration of L-PTC/B Okra . Taken together, these results indicate that N -glycosylated LRP1 mediates L-PTC/B Okra transcytosis via enterocytes, enabling BoNT to traverse the intestinal epithelial barrier.
Open AccessLRP1 is an entry receptor for the botulinum toxin complex in the gut
Botulinum neurotoxin (BoNT) is an etiologic agent of food poisoning caused by Clostridium botulinum . The large progenitor toxin complex (L-PTC) crosses the intestinal epithelial barrier to deliver BoNT to target neurons; however, it is not clearly understood how BoNT enters the host. Here, we identified low-density lipoprotein receptor−related protein 1 (LRP1) as a major enterocyte transcytosis receptor for the hyper-oral-toxic L-PTC serotype B-Okra (L-PTC/B Okra ). We found that hemagglutinin (HA), a neurotoxin-associated protein within the L-PTC/B Okra complex, binds to LRP1 via N -glycans. HA/B Okra co-localized with LRP1 within the internalized vesicles in cultured cells and enterocytes. LRP1 deletion inhibited the apical-to-basal transcytosis of L-PTC/B Okra in an intestinal epithelial cell line, and this effect was rescued by LRP1 re-expression. Finally, intestinal epithelial cell−specific LRP1-deficient mice displayed reduced susceptibility to toxicity caused by oral administration of L-PTC/B Okra . Taken together, these results indicate that N -glycosylated LRP1 mediates L-PTC/B Okra transcytosis via enterocytes, enabling BoNT to traverse the intestinal epithelial barrier.
- Open Access
- 8 January 2026
- Published by The Endocrine Society in Endocrinology
- Vol. 167 (2)
Selenoprotein P deletion ameliorates metabolic stress-associated anxiety-like behavior in male mice
Context: Diabetes-associated metabolic stress and anxiety reciprocally influence one another's onset and course. We previously linked excessive selenoprotein P (SeP, encoded by SELENOP in humans) to pathological conditions frequently observed in individuals with diabetes. Objective: The present study aimed to clarify the role of SeP in the metabolic stress-induced anxiety. Methods: We visualized Selenop expression in the mouse brain section via RNAscope in situ hybridization and used RT-qPCR to evaluate gene expression in brain regions. We created brain-specific Selenop knockout (bSelenop-/-) mice by mating Selenop-flox and Nestin-Cre mice and conducted behavior tests for anxiety-like behavior and spatial memory under both a standard (STD) and high-fat, high-sucrose diet (HFHSD) conditions. In a cross-sectional general population cohort study, we examined differences in serum selenoprotein P concentrations between individuals with and without anxiety symptoms. Results: RNAscope in situ hybridization identified glial and endothelial cells as the sources of SeP synthesis in the brain. Selenop was expressed at the same level in the brains of mice fed with an STD and HFHSD. bSelenop-/- mice did not exhibit altered body weight or glucose tolerance associated with HFHSD feeding. High-fat, high-sucrose diet aggravated the anxiety-like behavior in the control mice, whereas Selenop deletion in the brain ameliorated the anxiety-like behavior without affecting spatial memory. Epidemiological data revealed that serum selenoprotein P was significantly higher in subjects with anxiety symptoms. Conclusion/interpretation: These findings suggest that excess SeP production may be a common trait linking metabolic stress with anxiety.
- 8 January 2026
- Published by The Endocrine Society in Endocrinology
- Vol. 167 (2)
Open AccessSelenoprotein P deletion ameliorates metabolic stress-associated anxiety-like behavior in male mice
Context: Diabetes-associated metabolic stress and anxiety reciprocally influence one another's onset and course. We previously linked excessive selenoprotein P (SeP, encoded by SELENOP in humans) to pathological conditions frequently observed in individuals with diabetes. Objective: The present study aimed to clarify the role of SeP in the metabolic stress-induced anxiety. Methods: We visualized Selenop expression in the mouse brain section via RNAscope in situ hybridization and used RT-qPCR to evaluate gene expression in brain regions. We created brain-specific Selenop knockout (bSelenop-/-) mice by mating Selenop-flox and Nestin-Cre mice and conducted behavior tests for anxiety-like behavior and spatial memory under both a standard (STD) and high-fat, high-sucrose diet (HFHSD) conditions. In a cross-sectional general population cohort study, we examined differences in serum selenoprotein P concentrations between individuals with and without anxiety symptoms. Results: RNAscope in situ hybridization identified glial and endothelial cells as the sources of SeP synthesis in the brain. Selenop was expressed at the same level in the brains of mice fed with an STD and HFHSD. bSelenop-/- mice did not exhibit altered body weight or glucose tolerance associated with HFHSD feeding. High-fat, high-sucrose diet aggravated the anxiety-like behavior in the control mice, whereas Selenop deletion in the brain ameliorated the anxiety-like behavior without affecting spatial memory. Epidemiological data revealed that serum selenoprotein P was significantly higher in subjects with anxiety symptoms. Conclusion/interpretation: These findings suggest that excess SeP production may be a common trait linking metabolic stress with anxiety.
- Open Access
- 16 September 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (10) , 110730
Cysteine redoxome landscape in the liver of male mice fed a high-fat high-sucrose diet
- 16 September 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (10) , 110730
Open AccessCysteine redoxome landscape in the liver of male mice fed a high-fat high-sucrose diet
- Open Access
- 7 July 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (7) , e0326968
An in vitro model to study molecular pathogenesis of sarcopenia established by a SASP-dependent human myotube culture
Sarcopenia is a condition that affects one’s activities of daily livingand is rapidly increasing with the ages of the global population. However, the basic molecular mechanisms for prevention and treatment are not fully understood. Although rodent model animals have many valuable aspects for studying sarcopenia, some aspects and mechanisms differ from humans, such as immune response, metabolism, stress response, and myofiber composition. This study established a human cell-based in vitro model to elucidate the molecular mechanism by which SASP from senescence-induced human mesenchymal stem cells led to the narrowing of human myotube diameter, suggesting that this model is useful for studying sarcopenia. Gene expression profiling was performed the molecular mechanisms and devel on the model by RNA sequencing to identify genes whose expression was affected by SASP. Among these, the exposure to SASP upregulated PDK4 expression, and a PDK4 inhibitor, DCA, could increase myotube diameter and reverse SASP-mediated narrowing of the diameter. Pathway analyses suggested that SASP affected energy metabolism by activating OXPHOS and promoting the expression of mitochondrial function-related genes and mitochondrial biosynthesis factors. These results provide insights that contribute to developing new treatments for sarcopenia.
- 7 July 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (7) , e0326968
Open AccessAn in vitro model to study molecular pathogenesis of sarcopenia established by a SASP-dependent human myotube culture
Sarcopenia is a condition that affects one’s activities of daily livingand is rapidly increasing with the ages of the global population. However, the basic molecular mechanisms for prevention and treatment are not fully understood. Although rodent model animals have many valuable aspects for studying sarcopenia, some aspects and mechanisms differ from humans, such as immune response, metabolism, stress response, and myofiber composition. This study established a human cell-based in vitro model to elucidate the molecular mechanism by which SASP from senescence-induced human mesenchymal stem cells led to the narrowing of human myotube diameter, suggesting that this model is useful for studying sarcopenia. Gene expression profiling was performed the molecular mechanisms and devel on the model by RNA sequencing to identify genes whose expression was affected by SASP. Among these, the exposure to SASP upregulated PDK4 expression, and a PDK4 inhibitor, DCA, could increase myotube diameter and reverse SASP-mediated narrowing of the diameter. Pathway analyses suggested that SASP affected energy metabolism by activating OXPHOS and promoting the expression of mitochondrial function-related genes and mitochondrial biosynthesis factors. These results provide insights that contribute to developing new treatments for sarcopenia.
- Open Access
- 1 February 2024
- Published by Elsevier in The American Journal of Pathology
- Vol. 194 (5) , 693-707
Diabetes Accelerates Steatohepatitis in Mice
- 1 February 2024
- Published by Elsevier in The American Journal of Pathology
- Vol. 194 (5) , 693-707
Open AccessDiabetes Accelerates Steatohepatitis in Mice
- 1 June 2023
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 324 (6) , E542-E552
Selenoprotein P deficiency protects against immobilization-induced muscle atrophy by suppressing atrophy-related E3 ubiquitin ligases
Selenoprotein P (SeP) is a hepatokine that is upregulated in type 2 diabetes and aging and causes signal resistances via reductive stress. Immobilization (IMM) significantly reduced skeletal muscle mass in mice, which was prevented in SeP knockout (KO) mice. IMM-induced Foxos/KLF15-atrogene upregulation was suppressed in the skeletal muscle of KO mice. These findings suggest that SeP-mediated reductive stress is involved in and may be a therapeutic target for physical inactivity-mediated muscle atrophy.
- 1 June 2023
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 324 (6) , E542-E552
Selenoprotein P deficiency protects against immobilization-induced muscle atrophy by suppressing atrophy-related E3 ubiquitin ligases
Selenoprotein P (SeP) is a hepatokine that is upregulated in type 2 diabetes and aging and causes signal resistances via reductive stress. Immobilization (IMM) significantly reduced skeletal muscle mass in mice, which was prevented in SeP knockout (KO) mice. IMM-induced Foxos/KLF15-atrogene upregulation was suppressed in the skeletal muscle of KO mice. These findings suggest that SeP-mediated reductive stress is involved in and may be a therapeutic target for physical inactivity-mediated muscle atrophy.
- 1 June 2022
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 322 (6) , E556-E568
Lauric acid impairs insulin-induced Akt phosphorylation by upregulating SELENOP expression via HNF4α induction
Selenoprotein P (SeP; encoded by SELENOP in humans, Selenop in rodents) is a hepatokine that is upregulated in the liver of humans with type 2 diabetes. Excess SeP contributes to the onset of insulin resistance and various type 2 diabetes-related complications. We have previously reported that the long-chain saturated fatty acid, palmitic acid, upregulates Selenop expression, whereas the polyunsaturated fatty acids (PUFAs) downregulate it in hepatocytes. However, the effect of medium-chain fatty acids (MCFAs) on Selenop is unknown. Here, we report novel mechanisms that underlie the lauric acid-mediated Selenop gene regulation in hepatocytes. Lauric acid upregulated Selenop expression in Hepa1-6 hepatocytes and mice liver. A luciferase promoter assay and computational analysis of transcription factor-binding sites identified the hepatic nuclear factor 4α (HNF4α) binding site in the SELENOP promoter. A chromatin immunoprecipitation (ChIP) assay showed that lauric acid increased the binding of HNF4α to the SELENOP promoter. The knockdown of Hnf4α using siRNA canceled the upregulation of lauric acid-induced Selenop. The lauric acid-induced impairment of Akt phosphorylation brought about by insulin was rescued by the knockdown of either Hnf4α or Selenop. These results provide new insights into the regulation of SeP by fatty acids and suggest that SeP may mediate MCFA-induced hepatic insulin signal reduction. NEW & NOTEWORTHY Lauric acid induces hepatic insulin resistance by upregulating Selenop. These findings caution the metabolic risk of excessive lauric acid intake, especially in people with hepatic insulin resistance associated with type 2 diabetes.
- 1 June 2022
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 322 (6) , E556-E568
Lauric acid impairs insulin-induced Akt phosphorylation by upregulating SELENOP expression via HNF4α induction
Selenoprotein P (SeP; encoded by SELENOP in humans, Selenop in rodents) is a hepatokine that is upregulated in the liver of humans with type 2 diabetes. Excess SeP contributes to the onset of insulin resistance and various type 2 diabetes-related complications. We have previously reported that the long-chain saturated fatty acid, palmitic acid, upregulates Selenop expression, whereas the polyunsaturated fatty acids (PUFAs) downregulate it in hepatocytes. However, the effect of medium-chain fatty acids (MCFAs) on Selenop is unknown. Here, we report novel mechanisms that underlie the lauric acid-mediated Selenop gene regulation in hepatocytes. Lauric acid upregulated Selenop expression in Hepa1-6 hepatocytes and mice liver. A luciferase promoter assay and computational analysis of transcription factor-binding sites identified the hepatic nuclear factor 4α (HNF4α) binding site in the SELENOP promoter. A chromatin immunoprecipitation (ChIP) assay showed that lauric acid increased the binding of HNF4α to the SELENOP promoter. The knockdown of Hnf4α using siRNA canceled the upregulation of lauric acid-induced Selenop. The lauric acid-induced impairment of Akt phosphorylation brought about by insulin was rescued by the knockdown of either Hnf4α or Selenop. These results provide new insights into the regulation of SeP by fatty acids and suggest that SeP may mediate MCFA-induced hepatic insulin signal reduction. NEW & NOTEWORTHY Lauric acid induces hepatic insulin resistance by upregulating Selenop. These findings caution the metabolic risk of excessive lauric acid intake, especially in people with hepatic insulin resistance associated with type 2 diabetes.
- 1 April 2012
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 420 (4) , 931-936
Dicer has a crucial role in the early stage of adipocyte differentiation, but not in lipid synthesis, in 3T3-L1 cells
- 1 April 2012
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 420 (4) , 931-936
Dicer has a crucial role in the early stage of adipocyte differentiation, but not in lipid synthesis, in 3T3-L1 cells
- 6 July 2007
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 19 (8) , 621-631
5‐Aminoimidazole‐4‐Carboxamide‐1‐β‐4‐Ribofuranoside Stimulates Tyrosine Hydroxylase Activity and Catecholamine Secretion by Activation of AMP‐Activated Protein Kinase in PC12 Cells
The activity of AMP‐activated protein kinase (AMPK) is regulated by the metabolic and nutritional state of the cell. 5‐Aminoimidazole‐4‐carboxamide‐1‐β‐4‐ribofuranoside (AICAR) is transformed into riboside monophosphate (ZMP) via phosphorylation by adenosine kinase inside the cell and exerts it effect by stimulating AMPK. AICAR significantly induces an increase in AMPK activity in a dose‐ and time‐dependent manner in the rat pheochromocytoma cell line PC12. In addition, compound C, an AMPK inhibitor, as well as 5′‐amino‐5′‐dAdo, an adenosine kinase inhibitor, inhibits the AICAR‐induced AMPK activity. AICAR significantly stimulates tyrosine hydroxylase (TH) (the rate‐limiting enzyme in the biosynthesis of catecholamine) activity and the corresponding mRNA level, which closely matches with the TH protein level. In addition, AICAR provokes a rapid and long‐lasting increase in the phosphorylation of TH at Ser19, Ser31 and Ser40. AICAR also markedly activates ERKs, JNK and p38. The MEK‐1‐inhibitor (PD‐098059) causes a partial, but significant, inhibition of AICAR‐induced TH enzyme activity by phosphorylation of Ser31 without affecting phosphorylation at the two other sites. By contrast, neither the JNK‐inhibitor nor the p38‐inhibitor affects TH enzyme activity and phosphorylation. Similarly, PD‐098059 partially, but significantly, inhibits the AICAR‐induced increase in the TH mRNA level. Furthermore, AICAR increases the level of cAMP in PC12 cells. The present study also shows that H89, a protein kinase A inhibitor, abolishes the AICAR‐induced increase in the level of TH mRNA, as well as the corresponding enzyme activity and Ser40 phosphorylation. Finally, AICAR significantly increases dopamine secretion from PC12 cells. These findings indicate that AICAR activates catecholamine synthesis and secretion through AMPK activation in chromaffin cells.
- 6 July 2007
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 19 (8) , 621-631
5‐Aminoimidazole‐4‐Carboxamide‐1‐β‐4‐Ribofuranoside Stimulates Tyrosine Hydroxylase Activity and Catecholamine Secretion by Activation of AMP‐Activated Protein Kinase in PC12 Cells
The activity of AMP‐activated protein kinase (AMPK) is regulated by the metabolic and nutritional state of the cell. 5‐Aminoimidazole‐4‐carboxamide‐1‐β‐4‐ribofuranoside (AICAR) is transformed into riboside monophosphate (ZMP) via phosphorylation by adenosine kinase inside the cell and exerts it effect by stimulating AMPK. AICAR significantly induces an increase in AMPK activity in a dose‐ and time‐dependent manner in the rat pheochromocytoma cell line PC12. In addition, compound C, an AMPK inhibitor, as well as 5′‐amino‐5′‐dAdo, an adenosine kinase inhibitor, inhibits the AICAR‐induced AMPK activity. AICAR significantly stimulates tyrosine hydroxylase (TH) (the rate‐limiting enzyme in the biosynthesis of catecholamine) activity and the corresponding mRNA level, which closely matches with the TH protein level. In addition, AICAR provokes a rapid and long‐lasting increase in the phosphorylation of TH at Ser19, Ser31 and Ser40. AICAR also markedly activates ERKs, JNK and p38. The MEK‐1‐inhibitor (PD‐098059) causes a partial, but significant, inhibition of AICAR‐induced TH enzyme activity by phosphorylation of Ser31 without affecting phosphorylation at the two other sites. By contrast, neither the JNK‐inhibitor nor the p38‐inhibitor affects TH enzyme activity and phosphorylation. Similarly, PD‐098059 partially, but significantly, inhibits the AICAR‐induced increase in the TH mRNA level. Furthermore, AICAR increases the level of cAMP in PC12 cells. The present study also shows that H89, a protein kinase A inhibitor, abolishes the AICAR‐induced increase in the level of TH mRNA, as well as the corresponding enzyme activity and Ser40 phosphorylation. Finally, AICAR significantly increases dopamine secretion from PC12 cells. These findings indicate that AICAR activates catecholamine synthesis and secretion through AMPK activation in chromaffin cells.